Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort

This study underlines the potential role of ANA positivity as a predictive biomarker for the development of irAEs.
Source: Clinical and Experimental Medicine - Category: Research Source Type: research